压力性尿失禁与盆腔器官脱垂手术相关的围手术期阿片类药物处方
基于2005-2015年IBM MarketScan商业保险人群队列,纳入217,460例无阿片类药物使用史的女性,77.0%在围手术期(术前30天至术后7天)填写了阿片类药物处方,中位数量30片;术后90-180天填写处方的比例为7.5%(95%CI 7.3-7.6),而持续使用率在术后180天为0.06%(95%CI 0.05-0.08)、1年为0.04%(95%CI 0.02-0.05)。
要点
- 77.0%无阿片类药物使用史的女性在围手术期填写了阿片类药物处方,中位数量30片。
- 年轻年龄、盆腔器官脱垂手术(伴或不伴压力性尿失禁手术)、腹部路径、子宫切除和补片使用与填写阿片类药物处方显著相关。
- 延长使用(术后90-180天填写处方)风险为7.5%,持续使用率在术后180天和1年分别为0.06%和0.04%。
核心结论
- 在私下保险的无阿片类药物使用史女性中,77%在压力性尿失禁和/或盆腔器官脱垂手术围手术期填写了阿片类药物处方,中位数量30片;延长使用(术后90-180天填写处方)比例为7.5%(95%CI 7.3-7.6),持续填写处方率在术后180天为0.06%(95%CI 0.05-0.08)、1年为0.04%(95%CI 0.02-0.05)。
研究设计与样本
- 使用2005-2015年IBM MarketScan数据库中的商业保险人群队列,识别基于当前操作术语代码接受压力性尿失禁和/或盆腔器官脱垂手术的≥18岁无阿片类药物使用史女性。
- 围手术期定义为术前30天至术后7天的窗口,在此期间填写任何阿片类药物处方即视为围手术期处方。
- 共纳入217,460例无阿片类药物使用史的女性,其中61,025例(28.1%)接受盆腔器官脱垂和压力性尿失禁手术,85,575例(39.4%)接受压力性尿失禁手术不伴盆腔器官脱垂手术,70,860例(32.6%)接受盆腔器官脱垂手术不伴压力性尿失禁手术。
主要发现
- 总体167,354例(77.0%)填写了围手术期阿片类药物处方,中位数量30片(四分位距20-30)。
- 多变量回归模型中,年轻年龄、盆腔器官脱垂手术伴或不伴压力性尿失禁手术、腹部路径、子宫切除和补片使用仍与填写阿片类药物处方显著相关。
- 在填写围手术期阿片类药物处方者中,延长使用(术后90-180天填写处方)风险为7.5%(95%CI 7.3-7.6)。
- 持续使用(术后至少每月填写一次处方)风险在术后60天为1.2%(95%CI 1.13-1.24),90天为0.32%(95%CI 0.29-0.35),180天为0.06%(95%CI 0.05-0.08),360天为0.04%(95%CI 0.02-0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an opioid epidemic in the United States with a contributing factor of opioids being prescribed for postoperative pain after surgery. OBJECTIVE: Among women who underwent stress urinary incontinence and pelvic organ prolapse surgeries, our primary objective was to determine the proportion of women who filled perioperative opioid prescriptions and to compare factors associated with these opioid prescriptions. We also sought to assess the risk of prolonged opioid use through 1 year after stress urinary incontinence and pelvic organ prolapse surgeries. STUDY DESIGN: Using a population-based cohort of commercially insured individuals in the 2005-2015 IBM MarketScan databases, we identified opioid-naive women ≥18 years who underwent stress urinary incontinence and/or pelvic organ prolapse procedures based on Current Procedural Terminology codes. We defined the perioperative period as the window beginning 30 days before surgery extending until 7 days after surgery. Any filled opioid prescription in this window was considered a perioperative prescription. For our primary outcome, we reported the proportion of opioid-naive women who filled a perioperative opioid prescription and reported the median quantity dispensed in the perioperative period. We also assessed demographic and perioperative factors associated with perioperative opioid prescription fills. Previous studies have defined prolonged use as the proportion of women who fill an opioid prescription between 90 and 180 days after surgery. We report this estimate as well as continuous opioid use, defined as the proportion of women with ongoing monthly opioid prescriptions filled through 1 year after stress urinary incontinence and/or pelvic organ prolapse surgery. RESULTS: Among the 217,460 opioid-naive women who underwent urogynecologic surgery, 61,025 (28.1%) had pelvic organ prolapse and stress urinary incontinence surgeries, 85,575 (39.4%) had stress urinary incontinence surgery without pelvic organ prolapse surgery, and 70,860 (32.6%) had pelvic organ prolapse surgery without stress urinary incontinence surgery. Overall, 167,354 (77.0%) filled a perioperative opioid prescription, and the median quantity was 30 pills (interquartile range, 20-30). In a multivariate regression model, younger age, pelvic organ prolapse surgery with or without stress urinary incontinence surgery, abdominal route, hysterectomy, and mesh use remained significantly associated with opioid prescriptions filled. Among those with a filled perioperative opioid prescription, the risk of prolonged use defined as an opioid prescription filled between 90 and 180 days was 7.5% (95% confidence interval, 7.3-7.6). However, the risk of prolonged use defined as continuous use with at least 1 monthly opioid prescription filled after surgery was significantly lower: 1.2% (1.13-1.24), 0.32% (0.29-0.35), 0.06% (0.05-0.08), and 0.04% (0.02-0.05) at 60, 90, 180, and 360 days after surgery, respectively. CONCLUSION: Among privately insured, opioid-naive women undergoing stress urinary incontinence and/or pelvic organ prolapse surgery, 77% of women filled an opioid prescription with a median of 30 opioid pills prescribed. For prolonged use, 7.5% (95% confidence interval, 7.3-7.6) filled an opioid prescription within 90 to 180 days after surgery, but the rates of continuously filled opioid prescriptions were significantly lower at 0.06% (95% confidence interval, 0.05-0.08) at 180 days and 0.04% (95% confidence interval, 0.02-0.05) at 1 year after surgery.
引用
- Willis-Gray MG, Young JC, Pate V, et al. Perioperative opioid prescriptions associated with stress incontinence and pelvic organ prolapse surgery. Am J Obstet Gynecol. 2020. PMID: 32653459. doi:10.1016/j.ajog.2020.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。